Sign In
Buy KROS
$11.15
+0.500 (+4.69%)
At Close: Aug 07, 2026
Should Investors Buy, Sell or Hold KROS Stock Ahead of Q4 Earnings?
10:42am, Wednesday, 18'th Feb 2026
KROS investors eye pipeline updates as rinvatercept advances in DMD and Takeda-backed elritercept hits milestones ahead of Q4 results.
Keros Therapeutics vs. Dyne: Which DMD Biotech Has More Upside?
10:20am, Tuesday, 27'th Jan 2026
Keros Therapeutics KROS is a clinical-stage biopharmaceutical company developing innovative therapies for patients with disorders caused by abnormal signaling within the transforming growth factor-bet
Is KROS' KER-065 the Next Breakthrough in DMD Space?
10:16am, Monday, 26'th Jan 2026
KROS is advancing KER-065 for Duchenne muscular dystrophy, with orphan drug status and a phase II trial planned for early 2026.
Will KROS Stock's Restructuring Efforts Reap Rewards for Investors?
10:10am, Friday, 16'th Jan 2026
Keros Therapeutics sharpens focus on KER-065 for DMD, cuts staff 45%, shelves cibotercept, and plans a phase II trial in Q1 2026 with cash runway into 2028.
KROS Stock Surges 85.6% in a Year: More Upside Potential in 2026?
10:16am, Thursday, 15'th Jan 2026
KROS shares are up 85.6% in a year, driven by a strategic review and pipeline progress led by KER-065 and elritercept, which have fueled investor enthusiasm.
5 Low Price-to-Book Stocks to Buy as 2025 Comes to a Close
08:35am, Wednesday, 31'st Dec 2025
AES, BWA, ENS, PCG and KROS screen as low P/B stocks with Buy ratings, offering value-focused opportunities as 2025 comes to a close.
KROS or ARGX: Which Is the Better Value Stock Right Now?
12:40pm, Tuesday, 30'th Dec 2025
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Keros Therapeutics, Inc. (KROS) or argenex SE (ARGX). But which of these two stocks presents
Keros Therapeutics (KROS) Upgraded to Strong Buy: Here's Why
01:01pm, Monday, 22'nd Dec 2025
Keros Therapeutics (KROS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Here's Why Keros Therapeutics (KROS) Could be Great Choice for a Bottom Fisher
10:56am, Monday, 22'nd Dec 2025
Keros Therapeutics (KROS) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could
5 High-Risk, High-Reward Biotech Breakthrough Stocks to Watch in 2026
10:26am, Tuesday, 16'th Dec 2025
After a weak first half, the drug and biotech sector has recovered in the past 2-3 months with large drugmakers like Pfizer, AstraZeneca, Eli Lilly and Novo Nordisk signing drug pricing agreements wit
Buy These 5 Best Value Stocks to Boost Your Portfolio in December
10:16am, Monday, 15'th Dec 2025
Here we discuss five value stocks that are cheap in terms of price-to-book, price-to-sales and PEG. These are StoneCo, GM, EnerSys, Deutsche Bank and Keros.
What Makes Keros Therapeutics, Inc. (KROS) a Strong Momentum Stock: Buy Now?
01:01pm, Friday, 12'th Dec 2025
Does Keros Therapeutics, Inc. (KROS) have what it takes to be a top stock pick for momentum investors? Let's find out.
KROS vs. ARGX: Which Stock Is the Better Value Option?
12:41pm, Friday, 12'th Dec 2025
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Keros Therapeutics, Inc. (KROS) or argenex SE (ARGX). But which of these two companies is the
Keros Therapeutics, Inc. $KROS Stock Holdings Lowered by Federated Hermes Inc.
03:52am, Friday, 12'th Dec 2025
Federated Hermes Inc. lessened its position in Keros Therapeutics, Inc. (NASDAQ: KROS) by 46.6% during the second quarter, according to the company in its most recent 13F filing with the Securities an
Buy These 5 Best Value Stocks to Make the Most of P/B Ratio
10:55am, Friday, 28'th Nov 2025
Discover five low P/B picks like STNE that are undervalued and show solid growth potential based on value-focused filters.
